Dragan Sebisanovic
YOU?
Author Swipe
View article: Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Tumor marker levels and cfDNA mutant allele fractions across 19 time intervals for eight patients that were serially monitored via blood draws.
View article: Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Comparisons of CA 19-9 concentration and cfDNA mutant allele fractions in plasma. (A-E) cfDNA mutant allele fractions ("cfDNA percentage") versus CA 19-9 units per milliliter (U/mL) were determined at similar times for five patients with t…
View article: Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Tumor marker levels and cfDNA mutant allele fractions across 19 time intervals for eight patients that were serially monitored via blood draws.
View article: Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Complete patient-level and mutation-level concordance information, mutation identities, and monitoring status for each patient in study.
View article: Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Characteristics of the 26 patients in study.
View article: Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Complete patient-level and mutation-level concordance information, mutation identities, and monitoring status for each patient in study.
View article: Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Characteristics of the 26 patients in study.
View article: Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Comparisons of CA 19-9 concentration and cfDNA mutant allele fractions in plasma. (A-E) cfDNA mutant allele fractions ("cfDNA percentage") versus CA 19-9 units per milliliter (U/mL) were determined at similar times for five patients with t…
View article: Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in…
View article: Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
List of genes and exons captured in the Guardant360 cfDNA sequencing test.
View article: Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Supplementary Table 4 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
List of genes and exons captured in the Guardant360 cfDNA sequencing test.
View article: Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Data from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Open
Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in…
View article: Supplementary Figures 1-2 from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Supplementary Figures 1-2 from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Open
Supplementary Figures 1-2 from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
View article: Data from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Data from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Open
Missense variants are commonly identified in genomic sequence but only a small fraction directly contribute to oncogenesis. The ability to distinguish those missense changes that contribute to cancer progression from those that do not is a…
View article: Supplementary Figures 1-2 from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Supplementary Figures 1-2 from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Open
Supplementary Figures 1-2 from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
View article: Supplementary Methods from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Supplementary Methods from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Open
Supplementary Methods from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
View article: Supplementary Methods from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Supplementary Methods from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Open
Supplementary Methods from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
View article: Data from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms
Data from Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms Open
Missense variants are commonly identified in genomic sequence but only a small fraction directly contribute to oncogenesis. The ability to distinguish those missense changes that contribute to cancer progression from those that do not is a…